{"id":"afluria-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine works by introducing a small, harmless piece of the influenza virus to the body, which triggers an immune response and helps the body recognize and fight the virus in the future.","oneSentence":"Afluria Influenza Vaccine stimulates the body's immune system to produce antibodies against the influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:12.600Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza disease caused by influenza A and B viruses in individuals 6 months of age and older."}]},"trialDetails":[{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT07386509","phase":"EARLY_PHASE1","title":"WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-03-17","conditions":"Healthy","enrollment":2},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT05734040","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.","status":"COMPLETED","sponsor":"Osivax","startDate":"2023-05-10","conditions":"Influenza","enrollment":478},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT02947217","phase":"PHASE4","title":"Effect of Influenza Vaccination on IVF Outcomes - IVF","status":"UNKNOWN","sponsor":"Center for Human Reproduction","startDate":"2017-01-19","conditions":"Infertility","enrollment":238},{"nctId":"NCT03442582","phase":"","title":"Afluria Pregnancy Registry","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-09-08","conditions":"Influenza, Human, Pregnancy, Birth Defect","enrollment":490},{"nctId":"NCT04074928","phase":"PHASE3","title":"Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-09-06","conditions":"Influenza, Human, Virus Diseases","enrollment":2414},{"nctId":"NCT02946177","phase":"PHASE4","title":"Effect of Influenza Vaccination on Donor Egg Recipient Outcomes","status":"UNKNOWN","sponsor":"Center for Human Reproduction","startDate":"2017-01-19","conditions":"Infertility, Recurrent Miscarriage","enrollment":126},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT01248208","phase":"PHASE1, PHASE2","title":"FluMist in Egg Allergic Patients","status":"COMPLETED","sponsor":"Walter Reed Army Medical Center","startDate":"2010-09","conditions":"Egg Allergy, Eligible for Vaccination Against Influenza","enrollment":17},{"nctId":"NCT01591837","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2012-05","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT01857297","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-05","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT00735475","phase":"PHASE4","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-10","conditions":"Influenza","enrollment":1268},{"nctId":"NCT00902278","phase":"NA","title":"Immune Responses Induced by Different Licensed Influenza Vaccines","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2008-10","conditions":"Immune Response","enrollment":193},{"nctId":"NCT01688921","phase":"PHASE4","title":"Jet Injection for Influenza","status":"COMPLETED","sponsor":"PharmaJet, Inc.","startDate":"2012-10","conditions":"Influenza, Human","enrollment":1250},{"nctId":"NCT00959049","phase":"PHASE3","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-09","conditions":"Influenza","enrollment":1474},{"nctId":"NCT01825200","phase":"PHASE3","title":"Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2013-03","conditions":"Influenza","enrollment":2640}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Afluria"],"phase":"phase_2","status":"active","brandName":"Afluria Influenza Vaccine","genericName":"Afluria Influenza Vaccine","companyName":"Seqirus","companyId":"seqirus","modality":"Biologic","firstApprovalDate":"","aiSummary":"Afluria Influenza Vaccine stimulates the body's immune system to produce antibodies against the influenza virus. Used for Prevention of influenza disease caused by influenza A and B viruses in individuals 6 months of age and older..","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}